Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Egetis Therapeutics ABLTS:0ABW +3.74%54 Debt-to-Equity is 0.13 as of Jun. 2026, which is 38% below its 10-year median of 0.21. GuruFocus rates LTS:0ABW with a GF Score™ of 54/100 and a GF Value™ of kr5.29 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 954 Biotechnology companies, Egetis Therapeutics AB ranks better than 54.51% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Egetis Therapeutics AB's Debt-to-Equity or its related term are showing as below:
LTS:0ABW'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.21 Max: 0.35
Current: 0.13
During the past 13 years, the highest Debt-to-Equity Ratio of Egetis Therapeutics AB was 0.35. The lowest was 0.00. And the median was 0.21.
LTS:0ABW's Debt-to-Equity is ranked better than 54.51% of 954
companies
in the Biotechnology industry
Industry Median: 0.16
vs LTS:0ABW: 0.13
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Egetis Therapeutics AB Debt-to-Equity Related Terms
Egetis Therapeutics AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Egetis Therapeutics AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0ABW vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Egetis Therapeutics AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egetis Therapeutics AB (LTS:0ABW) has a Debt-to-Equity of 0.13 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Egetis Therapeutics AB and its competitors. This is 38% below median its historical median of 0.21. According to the industry distribution chart, Egetis Therapeutics AB ranks #434 out of 954 companies in the Biotechnology industry, placing it in the top 45.5%.
Is Egetis Therapeutics AB's Debt-to-Equity too high?
Egetis Therapeutics AB's current Debt-to-Equity of 0.13 is 38% below median its 10-year median of 0.21. The Biotechnology industry median Debt-to-Equity is 0.16. Egetis Therapeutics AB's value of 0.13 is 18.8% below this industry median. Based on the distribution chart, Egetis Therapeutics AB ranks #434 out of 954 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Egetis Therapeutics AB has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #434 out of 954 companies for Debt-to-Equity. This puts Egetis Therapeutics AB in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Egetis Therapeutics AB's value of 0.13 is 18.8% below this benchmark. While the company's 10-year median is 0.21 vs. the industry median of 0.16, Egetis Therapeutics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egetis Therapeutics AB's current Debt-to-Equity of 0.13 is 18.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Egetis Therapeutics AB and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egetis Therapeutics AB's current Debt-to-Equity is 0.13, which is 38% below median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (LTS:0ABW) is currently considered Significantly Overvalued. The stock's GF Value™ is kr5.29, compared to a current price of kr7.08 — trading 33.7% above its estimated fair value. The current Debt-to-Equity is 0.13, which is 38% below median its 10-year median of 0.21 and 18.8% below the Biotechnology industry median of 0.16. Egetis Therapeutics AB's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Egetis Therapeutics AB (LTS:0ABW), the current Debt-to-Equity is 0.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (LTS:0ABW) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued.
The current stock price of kr7.08 is trading 33.7% above its estimated GF Value™ of kr5.29.
GuruFocus considers Egetis Therapeutics AB to be Significantly Overvalued.
Key valuation signals for LTS:0ABW:
Debt-to-Equity: 0.13 (38% below median its 10-year median of 0.21)
GF Value™: kr5.29 vs. price of kr7.08 (33.7% above fair value)
Industry Position: 18.8% below the Biotechnology median (#434 of 954)
No single metric tells the full story. See the LTS:0ABW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
54GF Score
Get the complete analysis for LTS:0ABW
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0ABW has been successfully added to your 
